The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants. This facility, in Denmark, is the second Novo plant dinged for potential contamination issues — the other is in North Carolina. The Denmark issue is bad enough that the company doesn’t expect it to be resolved this year.